Please assess the completion status of the following clinical trial:

Trial Title: The VISION Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 12-85 years; of either gender.~* Confirmed PAH due to idiopathic pulmonary arterial hypertension (IPAH) or familial pulmonary arterial hypertension (FPAH).~* 6-minute walk distance (6-MWD) between 100-450 meters at screening.~* On a stable dose of sildenafil, with or without bosentan.~Exclusion Criteria:~* Any treatment for PAH with prostacyclins, prostacyclin analogues, endothelin-1 antagonists, or phosphodiesterase-5 (PDE-5) inhibitors other than sildenafil within the past 12 weeks.~* Pulmonary hypertension due to conditions other than those stated in inclusion criteria.~* Additional PAH medications added within the past 12 weeks.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- DB inhaled iloprost 6x/day (Type: EXPERIMENTAL): inhaled iloprost (5 μg) 6 times per day (6×/day) plus sildenafil with or without bosentan during the double blind period
- DB inhaled iloprost 4x/day (Type: EXPERIMENTAL): Inhaled iloprost (5 μg) 4×/day plus inhaled placebo 2x/day plus sildenafil with or without bosentan during the double blind period
- DB inhaled placebo 6x/day (Type: PLACEBO_COMPARATOR): Inhaled placebo 6×/day plus sildenafil with or without bosentan during the double blind period
- OL inhaled iloprost 6x/day (Type: EXPERIMENTAL): Inhaled iloprost (5 μg) 6 times per day (6×/day) plus sildenafil with or without bosentan during the Open-Label treatment period
- OL inhaled iloprost 4x/day (Type: EXPERIMENTAL): Inhaled iloprost (5 μg) 4 times per day (4×/day) plus sildenafil with or without bosentan during the Open-Label treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).